Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02393547 · ClinicalTrials.gov registry record · Phase 1
Lorcaserin for Preventing Weight Gain Among Smokers
A Phase 1 study of Tobacco Use Disorder and Weight Gain, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02393547: Completed Phase 1 study of Tobacco Use Disorder and Weight Gain, sponsored by Mayo Clinic.
NCT02393547 is a Phase 1 study of Tobacco Use Disorder and Weight Gain that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02393547, a Phase 1 study of Tobacco Use Disorder and Weight Gain, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be an open label clinical trial with all subjects receiving both lorcaserin and varenicline with a primary aim of reducing post cessation weight gain.
Primary Outcome
change in weight from baseline to week 12
Conditions Studied
Interventions
- DRUG Varenicline
- DRUG Lorcaserin
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-09 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
What the finished NCT02393547 record still lists
NCT02393547 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Tobacco Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Varenicline is the first listed.
NCT02393547 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02393547 about?
NCT02393547 is a clinical study titled "Lorcaserin for Preventing Weight Gain Among Smokers". This will be an open label clinical trial with all subjects receiving both lorcaserin and varenicline with a primary aim of reducing post cessation weight gain.
What is the current status of trial NCT02393547?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2013-09. Estimated completion is 2015-12.
What conditions does trial NCT02393547 study?
This clinical trial studies the following conditions: Tobacco Use Disorder, Weight Gain.
What interventions are being tested in trial NCT02393547?
The interventions under investigation include: Varenicline (DRUG), Lorcaserin (DRUG).
Who is sponsoring clinical trial NCT02393547?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02393547 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02393547's enrollment target sits among peer trials
20 68th of 70 higher than 3 of 70 other Tobacco Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tobacco Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Oral Cannabidiol for Tobacco Cessation
RECRUITING · Phase 1
-
Persistence-Targeted Smoking Cessation
COMPLETED · Phase 1
-
Project 3, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in People With Current Affective Disorders
COMPLETED · Phase 1
-
Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals - 3
COMPLETED · Phase 1
-
Brain Imaging in Tobacco Smokers During a Quit Attempt
COMPLETED · Phase 1
-
Project 2, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Opioid Abusers
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia